

Johnson and Johnson

[View the current Johnson and Johnson Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/5365-Johnson+and+Johnson.html)

(<http://www.bioportfolio.com/biocorporate/5365-Johnson+and+Johnson.html>)

Contact Details:

P.O. Box 726

Langhorne

PA

19047-0726

United States of America

Tel:

Fax:

Email:

Johnson & Johnson, employing approximately 119,000 people worldwide, is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. Johnson & Johnson's primary interest, both historically and currently, has been in products related to health and well-being. Johnson & Johnson was organized in the State of New Jersey in 1886.

Recent Publications by Johnson and Johnson:



- [Fluorescence and coloration of grey hair.](#)
*Grey hair samples were collected from 11 individuals and separated into...*18th November, 2009
Johnson and Johnson, Consumer Products Division, Skillman, NJ, USA.- Int J Cosmet Sci. 2009 Oct;31(5):347-59. ([DOI Direct Link](#))
- [Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells.](#)
*BACKGROUND: Hematopoietic stem cells (HSC), in particular mobilized...*11th November, 2009
Johnson and Johnson Research Pty Ltd., Eveleigh, New South Wales,- PLoS One. 2009 Jul 30;4(7):e6461. ([DOI Direct Link](#))
- [Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success.](#)
*BACKGROUND: Multiple short hairpin RNA (shRNA) gene therapy strategies are...*3rd November, 2009
Johnson and Johnson Research Pty Ltd, Level 4 Biomedical Building,- Virol J. 2009 Oct 30;6:184. ([DOI Direct Link](#))
- [Pharmacometrics-Based Dose Selection of Levofloxacin as a Treatment for Post-Exposure Inhalational Anthrax in Children.](#)
*Levofloxacin was recently (May 2008) approved by U.S. Food and Drug...*28th October, 2009

Division of Pharmacometrics, Office of Clinical Pharmacology, Center for- Antimicrob Agents Chemother. 2009 Oct 26. ([DOI Direct Link](#))

- [Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer.](#)
*BACKGROUND: MicroRNAs (MiRNAs) are short non-coding RNAs that control...*22nd October, 2009 Johnson and Johnson Research Pty Ltd, Eveleigh, NSW, Australia.- BMC Cancer. 2009 Oct 20;9:374. ([DOI Direct Link](#))
- [Sequence determinants of innate immune activation by short interfering RNAs.](#)
*BACKGROUND: Short interfering RNAs (siRNAs) have been shown to induce...*22nd October, 2009 Johnson and Johnson Research Pty Ltd, Strawberry Hills, NSW, Australia.- BMC Immunol. 2009 Jul 24;10:40. ([DOI Direct Link](#))
- [Role of Janus kinase-2 in IgE receptor-mediated leukotriene C\(4\) production by mast cells.](#)
*We have previously shown that Janus kinase 3, a member of the family of...*20th October, 2009 Johnson and Johnson Consumer and Personal Products Worldwide, Skillman,- Biochem Biophys Res Commun. 2009 Oct 14. ([DOI Direct Link](#))
- [96 shRNAs designed for maximal coverage of HIV-1 variants.](#)
*BACKGROUND: The RNA interference (RNAi) pathway is a mechanism of...*6th October, 2009 Johnson and Johnson Research Pty Ltd, Australian Technology Park,- Retrovirology. 2009 Jun 4;6:55. ([DOI Direct Link](#))
- [Primary leukocyte screens for innate immune agonists.](#)
*The innate immune system of mammals is a key defense mechanism against...*1st October, 2009 Johnson and Johnson Research Pty Ltd, Strawberry Hills NSW, Australia.- J Biomol Screen. 2009 Jul;14(6):723-30. Epub 2009 Jun 12. ([DOI Direct Link](#))
- [The role of keratinocyte growth factor in melanogenesis: a possible mechanism for the initiation of solar lentigines.](#)
*Please cite this paper as: The role of keratinocyte growth factor in...*29th September, 2009 The Johnson and Johnson Skin Research Center, Consumer Product Worldwide,- Exp Dermatol. 2009 Sep 23. ([DOI Direct Link](#))
- [An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS\(R\) hydromorphone in patients with chronic cancer pain.](#)
*ABSTRACT: BACKGROUND: Opioid analgesics have proven efficacy in the...*17th September, 2009 Johnson and Johnson Pharmaceutical Research Division Corporation, 6500- BMC Palliat Care. 2009 Sep 15;8:14. ([DOI Direct Link](#))
- [Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex.](#)
*Norfluoxetine is the most important active metabolite of the widely used...*6th August, 2009 Johnson and Johnson Pharmaceutical Research and Development, L. L. C.,- Pharmacol Biochem Behav. 2009 May;92(3):469-73. Epub 2009 Feb 5. ([DOI Direct Link](#))
- [Heat-killed Propionibacterium acnes is capable of inducing inflammatory responses in skin.](#)
*Please cite this paper as: Heat-killed Propionibacterium acnes is capable...*25th July, 2009 Preclinical Pharmacology, Skin Research Center, Johnson and Johnson- Exp Dermatol. 2009 Jul 14. ([DOI Direct Link](#))
- [A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice.](#)
*BACKGROUND: The mammalian target of rapamycin protein (mTOR) is an...*22nd May, 2009 Inflammation Research Team, Drug Discovery, Johnson and Johnson- BMC Immunol. 2009 May 20;10:28. ([DOI Direct Link](#))
- [Cleaved secretory leucocyte protease inhibitor as a biomarker of chymase activity in allergic airway disease.](#)
*BACKGROUND: Secretory leucocyte protease inhibitor (SLPI), which is...*30th April, 2009 Johnson and Johnson Pharmaceutical Research and Development, Spring House,- Clin Exp Allergy. 2009 Aug;39(8):1179-86. Epub 2009 Apr 7. ([DOI Direct Link](#))

Press Releases on Johnson and Johnson:

DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years	24th November, 2009	DynaVox Mayer-Johnson	PITTSBURGH, Nov. 24 /PRNewswire/ -- WHAT: Rom Houbens, a Belgian man thought to have been in coma for 23 years following an auto accident, was actually fully conscious and awake during that time and
New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS	24th November, 2009	Pharmaceutical Research and Manufacturers of America	WASHINGTON, Nov. 24 /PRNewswire-USNewswire/ -- America's pharmaceutical research and biotechnology companies are testing 97 medicines and vaccines to treat or prevent HIV/AIDS and related
NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director	24th November, 2009	NeurogesX, Inc.	SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today
Pearl Therapeutics Appoints Howie Rosen to Board of Directors	23rd November, 2009	Pearl Therapeutics Inc.	REDWOOD CITY, Calif., Nov. 23 /PRNewswire/ -- Pearl Therapeutics Inc., a biopharmaceutical company developing therapeutic products for the treatment of chronic respiratory diseases, today announced
Inimex Announces Appointment of New CEO	23rd November, 2009	Inimex Pharmaceuticals Inc.	BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. announced today that it has appointed Michael J. Abrams, Ph.D as its President and CEO. Abrams brings more than 25 years of drug

BioNews Results for Johnson and Johnson



- [Girding against germs: Flu outbreak in area spurs disinfectant, sanitizer sales germs](#)
TMC Net: Nov 22 2009 10:40PM Matching: johnson
- [Girding against germs: Flu outbreak in area spurs disinfectant, sanitizer sales germs](#)
Toledoblade.com: Nov 22 2009 3:02PM Matching: johnson
- [Movetis seeking up to 112.4 million euros in IPO](#)
Imaging Economics: Nov 21 2009 12:51PM Matching: johnson

- [Swine flu vaccine clinic is expanded](#)
Abilene Reporter: Nov 21 2009 9:37PM Matching: johnson
- [BMS splits off Mead Johnson, signs potential \\$1 billion deal with Alder Biopharmaceuticals in quest to become](#)
Drug Discovery News: Nov 20 2009 4:19PM Matching: johnson
- [Johnson and Johnson \(JNJ\) 11/20/09 PriceWatch Alert Could Hit 5.12% Return](#)
Market Intelligence Center: Nov 20 2009 7:54PM Matching: johnson
- [Movetis seeking up to 112.4 million euros in IPO](#)
Forbes.com: Nov 20 2009 9:55AM Matching: johnson
- [Movetis seeking up to 112.4 million euros in IPO](#)
Reuters: Nov 20 2009 9:53AM Matching: johnson
- [Movetis seeking up to 112.4 million euros in IPO](#)
Interactive Investor International: Nov 20 2009 9:42AM Matching: johnson
- [Correction: Plavix story](#)
Seattle Times: Nov 20 2009 3:45PM Matching: johnson
- [Johnson Hospital to go on the market in the new year SPALDING'S old Johnson Hospital might not go on the marke](#)
Spalding Guardian: Nov 20 2009 1:07AM Matching: johnson
- [Johnson and Johnson \(JNJ\) 11/18/09 PriceWatch Alert Targets 5.73% Return](#)
Market Intelligence Center: Nov 19 2009 10:05AM Matching: johnson
- [Bristol-Myers Squibb Announces Split-Off of Mead Johnson](#)
PipelineReview: Nov 19 2009 11:30AM Matching: johnson
- [Johnson & Johnson Q2 2007 Earnings Call Transcript](#)
Seeking Alpha: Nov 18 2009 9:27AM Matching: johnson
- [Gubernatorial candidates campaign here](#)
Jesup Press-Sentinel: Nov 18 2009 5:31AM Matching: johnson

Johnson and Johnson Clinical Trials:



- [A Multicenter Postmarket Surveillance Registry Evaluating the Performance and Long Term Safety of the Presillion Stent in de Novo Native Coronary Artery Lesions: Iberian Registry](#)

Johnson and Johnson Patents:



- 7039984- [Handle for tooth cleaning member](#)
- 6509388- [Polyurethane foams for use in wound dressings](#)
- 5879282- [Catheter having an expandable radioactive source](#)

- 4911932- [Skin care compositions](#)
- 4430061- [Orthodontic bracket assembly](#)
- 4406620- [Facebow swivel](#)
- 4401773- [Highly reactive ion-leachable glass](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:Peter.Barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

